Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Predix Pharmaceuticals Ltd.

Division of Epix Pharmaceuticals Inc.

Latest From Predix Pharmaceuticals Ltd.

Computational Drug Discovery

Computational drug discovery companies promise to unite data from many of the disparate steps pharmaceutical companies go through these days, to enable more efficient lead identification, optimization, and testing.

G-Protein Coupled Receptors

It has always been popular to start companies around families and subfamilies of targets, banking on the similarity among the receptors to speed drug discovery. But the idea largely hasn't panned out, in part because of the new target risk--sometimes they're not pharmaceutically relevant and sometimes they resist the available chemistries. That's why G-protein coupled receptors (GPCRs) have been so important: they're clearly relevant (many, perhaps most, blockbusters come from this class of receptor) and their unique structure makes them both relatively easy to hit with ligands and likely to do something when hit. But the same structural advantages turn into scientific disadvantages for researchers: they resist screening and other techniques of modern drug discovery. We explore some of the newest approaches to mining this rich vein of opportunity.
BioPharmaceutical Leadership

Bio Information Technologies Ltd.

The hunt for drugs that act on G-protein coupled receptors (GPCR) presents a unique challenge in drug discovery, because pharmaceutical researchers don't possess the three-dimensional structure of a single therapeutically relevant GPCR, crucial information that provides a starting point for understanding the function of a receptor, and then designing drugs that bind to it. The founders of Bio-IT have created a program that works at the atomic level to predict the three-dimensional structures of GPCRs. The model uses as inputs amino acid sequence information, geometric algorithms, and physicochemical factors.
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Bioinformatics
      • Genomics-Proteomics
    • Large Molecule
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Bio-IT Pharmaceuticals Ltd.
  • Bio Information Technologies Ltd.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Middle East
      • Israel
  • Parent & Subsidiaries
  • Epix Pharmaceuticals Inc.
  • Senior Management
  • Michael A Kauffman, MD, PhD, Pres. & CEO
    Dale S Dhanoa, PhD, SVP, R&D
    Oren M Becker, PhD, CTO
  • Contact Info
  • Predix Pharmaceuticals Ltd.
    Phone: (972) 3 612 8590
    SAP Building, 11th Fl.
    3 Hayetzira St.
    Ramat Gan, 52521